Literature DB >> 9445300

Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis.

J A Bjoraker1, J H Ryu, M K Edwin, J L Myers, H D Tazelaar, D R Schroeder, K P Offord.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a generally fatal disorder with a reported median survival of 3 to 6 yr. This has been based on relatively few studies with diagnoses inconsistently confirmed by adequate lung biopsy. Retrospective analysis of 104 patients with IPF who had open lung biopsy (OLB) at Mayo Medical Center from 1976 to 1985 was performed to establish the overall survival rate, the spectrum of histopathological subgroups and their associated prognostic significance. The study group consisted of 54 men and 50 women with a median age of 63 yr. Median survival was 3.8 yr after diagnosis by OLB with an estimated 10 yr survival of 27%. Current histopathologic review showed a heterogeneous group including usual interstitial pneumonia (UIP), desquamative interstitial pneumonia (DIP), nonspecific interstitial pneumonia/fibrosis (NSIP), acute interstitial pneumonia (AIP), bronchiolitis, bronchiolitis obliterans organizing pneumonia (BOOP), and others. Median survival of the UIP group was 2.8 yr which is significantly worse (p < 0.001) than for other subgroups of chronic interstitial pneumonias. IPF includes several histopathologic subgroups with significantly different survival rates. Patients with UIP have worse survival than patients with other types of idiopathic chronic interstitial pneumonias including NSIP. Accurate histopathologic classification is essential for prognostication in patients with IPF.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9445300     DOI: 10.1164/ajrccm.157.1.9704130

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  215 in total

Review 1.  Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis.

Authors:  A Wells
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 2.  Lung fibrosis.

Authors:  C Fonseca; D Abraham; C M Black
Journal:  Springer Semin Immunopathol       Date:  1999

3.  Serum sialyl Lewis X-i antigen in lung adenocarcinoma and idiopathic pulmonary fibrosis.

Authors:  H Satoh; H Ishikawa; Y T Yamashita; M Ohtsuka; K Sekizawa
Journal:  Thorax       Date:  2002-03       Impact factor: 9.139

Review 4.  Review of cryptogenic fibrosing alveolitis, including current treatment guidelines.

Authors:  S C Bourke; H Clague
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

5.  [Pulmonary fibrosis. Classification, diagnosis, therapy].

Authors:  U Costabel; J Guzman
Journal:  Internist (Berl)       Date:  2003-06       Impact factor: 0.743

Review 6.  Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches.

Authors:  Moisés Selman; Victor J Thannickal; Annie Pardo; David A Zisman; Fernando J Martinez; Joseph P Lynch
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 7.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

Review 8.  Interstitial lung disease in systemic sclerosis.

Authors:  Predrag Ostojic; Marco Matucci Cerinic; Richard Silver; Kristin Highland; Nemanja Damjanov
Journal:  Lung       Date:  2007 Jul-Aug       Impact factor: 2.584

9.  Protein Tyrosine Phosphatase-N13 Promotes Myofibroblast Resistance to Apoptosis in Idiopathic Pulmonary Fibrosis.

Authors:  Alison Bamberg; Elizabeth F Redente; Steve D Groshong; Rubin M Tuder; Carlyne D Cool; Rebecca C Keith; Benjamin L Edelman; Bart P Black; Gregory P Cosgrove; Murry W Wynes; Douglas Curran-Everett; Stijn De Langhe; Luis A Ortiz; Andrew Thorburn; David W H Riches
Journal:  Am J Respir Crit Care Med       Date:  2018-10-01       Impact factor: 21.405

10.  A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia.

Authors:  Nobuhiro Matsumoto; Shigeki Katoh; Shigehisa Yanagi; Yasuji Arimura; Masatoshi Tokojima; Masaki Ueno; Mitsuomi Hirashima; Masamitsu Nakazato
Journal:  Lung       Date:  2013-01-16       Impact factor: 2.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.